Hunan Hansen Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hunan Hansen Pharmaceutical Co., Ltd. (stock code 002412) was listed on the SME board of the Shenzhen Stock Exchange in May 2010. It was the first local enterprise in Yiyang City to go public, formerly known as Hunan Yiyang Pharmaceutical Factory. The company's headquarters is located in Longling Industrial Development Zone, Heshan District, Yiyang City. It has jurisdiction over Hansen Health Industry (Hunan) Co., Ltd., Hunan Hansen Pharmaceutical Research Co., Ltd., and Yunnan Yongzitang Pharmaceutical Co., Ltd. The company mainly produces traditional Chinese medicine preparations, supplemented by chemical drugs, and its products mainly involve digestive system medication, cardiovascular and cerebrovascular medication, kidney tonifying and diuretic medication, trauma medication, and diagnostic medication. The leading products include Simo Tang oral liquid, Ginkgo biloba capsule, Shuoquan capsule, etc. The company has multiple invention patents, and the "Hansen" trademark is a "well-known trademark in China". The research project of Simotang oral liquid has been selected for the national "973" plan, and it has research and development platforms such as the Hunan Provincial Enterprise Technology Center, the Hunan Provincial Digestive Medicine Engineering Technology Research Center, and the Hunan Provincial University "Innovative Drug Research and Development" Industry University Research and Research Cooperation Demonstration Base. The future development plan is: stick to the main business of traditional Chinese patent medicines and simple preparations - continue to be the market of Hansen Simotang oral liquid, and make products such as Suoquan capsule into star products; Focusing on Tianma Xingnao Capsules, we aim to create the first brand of modern plateau botanical medicine; Continuously develop new products that reflect the unique advantages of traditional Chinese medicine, timely develop chemical medicine products suitable for disease spectrum, and screen and incubate several biopharmaceutical industry projects. Extending the Great Health Industry - relying on a health industry park with an area of over 2500 acres, the industry extends to upstream and downstream fields such as the construction of traditional Chinese medicine bases and medical care; Develop several major health products based on the concept of "food and medicine are of the same origin". Integrating the financial industry - relying on the joint establishment of Sanxiang Bank with Sany Group and others to enhance the profitability and overall competitiveness of enterprises. Based on the traditional Chinese medicine industry, we aim to expand and integrate the industry, and strive to become one of the top 50 pharmaceutical companies in China, becoming a leading comprehensive pharmaceutical enterprise in the country. |
| Headquarter | Yiyang |
| Establish Date | 1/21/1998 |
| Listed Code | 002412.SZ |
| Listed Date | 5/25/2010 |
| Chairman | Liu Zhengqing. |
| CEO | Liu Zhengqing. |
| Website | www.hansenzy.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
